16,278 reports of this reaction
5.3% of all RANITIDINE reports
#5 most reported adverse reaction
RENAL CANCER is the #5 most commonly reported adverse reaction for RANITIDINE, manufactured by Ajanta Pharma USA Inc.. There are 16,278 FDA adverse event reports linking RANITIDINE to RENAL CANCER. This represents approximately 5.3% of all 308,223 adverse event reports for this drug.
RANITIDINE has an overall safety score of 95 out of 100. Patients taking RANITIDINE who experience renal cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL CANCER is moderately reported among RANITIDINE users, representing a notable but not dominant share of adverse events.
In addition to renal cancer, the following adverse reactions have been reported for RANITIDINE:
The following drugs have also been linked to renal cancer in FDA adverse event reports:
RENAL CANCER has been reported as an adverse event in 16,278 FDA reports for RANITIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL CANCER accounts for approximately 5.3% of all adverse event reports for RANITIDINE, making it a notable side effect.
If you experience renal cancer while taking RANITIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.